The Genio system is a battery-free, leadless and minimally invasive neurostimulator, which delivers bilateral hypoglossal nerve stimulation for the treatment of moderate to severe OSA. Image Credit: Pixel-Shot / Shutterstock.

Nyxoah’s hypoglossal nerve stimulation system, Genio, met the co-primary endpoints at 12 months in the pivotal DREAM trial in adults with obstructive sleep apnoea (OSA).

OSA is a sleep disorder where the walls of the throat relax and narrow during sleep, interrupting normal breathing and leading to interrupted sleep. Common treatments include using a continuous positive airway pressure (CPAP) device and a mandibular advancement device (MAD) – both prevent airway closure.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The open-label DREAM trial (NCT03868618) enrolled 115 patients in multiple sites across the US, Australia, Belgium and Germany. One of the study’s co-primary endpoints was a reduction of at least 50% and an apnoea-hypopnea index (AHI), which is the combined average number of apnoea and hypopneas that occur per hour of sleep, of 20 events per hour post-treatment. The second co-primary endpoint was the number of participants achieving a 4% oxygen desaturation index (ODI), which is the number of times per hour of sleep that the blood oxygen level drops by ≥4 percentage points from baseline.

At 12 months, participants had a median AHI reduction of 70.8%. The study had an ODI responder rate of 71.3%. The trial had a serious adverse event rate of 8.7%. Nyxoah plans to seek market authorisation in the US based on the DREAM trial data.

The Genio system is a battery-free, leadless and minimally invasive neurostimulator, which delivers bilateral hypoglossal nerve stimulation for the treatment of moderate to severe OSA. In 2019, the device received a CE mark for treating patients with moderate to severe OSA with an AHI equal to or greater than 15, but less than 65 events/hour.

See Also:

The global annual market for OSA detection and treatment is worth approximately $10bn, as per GlobalData analysis and CPAP devices dominate the market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Multiple companies are developing novel treatments for OSA. For instance, StimAire is developing an injectable stimulator device, which was designed to modulate peripheral nerves such as the hypoglossal. It uses a tiny, battery-free, injectable receiver/stimulator that is activated by a small wearable.

In January 2023, Vivos Therapeutics received 510(k) clearance from the US Food and Drug Administration (FDA) for its DNA oral appliance (daytime-nighttime appliance) for treating mild to moderate OSA. The device acts similarly to a MAD by opening the airway by extending the palate and training the tongue to rest in the proper position, as well as converting patients to nasal instead of oral breathing. The device trial showed OSA resolution in 28% of patients, with 63% of patients showing improvement by one AHI classification and 86% of patients improving their airway size.